Ipca Laboratories Limited (IPCALAB)
ISIN: INE571A01038 Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
980.95
16.15(1.67%)

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. It also provides generic and branded formulations in the therapeutic segments, including cardiology, gastroenterology, dermatology, rheumatology, urology, ophthalmology, infectious disease, immunosuppressant, probiotics, respiratory, allergy, nutraceuticals, anti-neoplastic, malarial, neurology, psychiatry, orthopedics, helminthics, fever, hematology, hepatoprotective, diabetology, anti-epileptic, emollients/protectives, NSAIDs, rheumatology, anti-arthritic, and neuropathic pain, as well as products in various dosage forms comprising oral solids, powders for suspension, and liquid and dry injections. The company exports its products to approximately 100 countries worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

Pricing Updates

TODAY'S HIGH

991.85

TODAY'S LOW

966

52 WEEK HIGH

1383.1

52 WEEK LOW

925.2

Major Holders

% of Shares Held by
All Insider

46.69%

% of Shares Held by
Institutions

39.12%

% of Float Held by
Institutions

73.38%

Number of Institutions
Holding Shares

102

Company Overview

MARKET CAP

24887.09 Cr.

ETERPRISE VALUE

24449.89 Cr.

NO. OF SHARES

25.37 Cr.

BOOK VALUE

207.519

DIV. YIELD

4%

DEBT

306.75 Cr.

GROSS PROFIT

3524.24 Cr.

CASH

969.06 Cr.

REVENUE

5656.08 Cr.

REVENUE/SHARE

222.926

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Investments-150.09 Cr.-166.05 Cr.-14.58 Cr.6.58 Cr.
Change To Liabilities55.95 Cr.68.28 Cr.101.88 Cr.26.35 Cr.
Total cashflows from Investing Activities-520.69 Cr.-509.65 Cr.-165.06 Cr.-135.40 Cr.
Net Borrowings-231.69 Cr.-10.81 Cr.-174.60 Cr.-92.63 Cr.
Total Cash from Financing Activities-305.82 Cr.-136.54 Cr.-183.20 Cr.-130.41 Cr.
Other Liabilities-117.34 Cr.95.30 Cr.43.55 Cr.-17.16 Cr.
Total Assets35.81 Cr.35.81 Cr.4.57 Cr.4.57 Cr.
Net Income1140.01 Cr.606.32 Cr.444.83 Cr.239.42 Cr.
Change in Cash263.62 Cr.-75.53 Cr.152.77 Cr.75.32 Cr.
Effect of Exchange Rate0000
Total Cash from Operating Activities1090.13 Cr.570.35 Cr.501.03 Cr.341.13 Cr.
Depreciation203.46 Cr.206.01 Cr.176.34 Cr.170.83 Cr.
Other Cashflows from Investing Activities-11.62 Cr.58.75 Cr.28.19 Cr.-6.40 Cr.
Dividends Paid-101.53 Cr.-100.89 Cr.-12.81 Cr.-12.76 Cr.
Change to Inventory-271.69 Cr.-239.86 Cr.-191.91 Cr.1.63 Cr.
Change to Account Receivables96.75 Cr.-187.41 Cr.-75.49 Cr.-95.26 Cr.
Other Cashflows from Financing Activities-8.41 Cr.-24.84 Cr.-36 Lakhs-25.02 Cr.
Change to Net Income-22.72 Cr.17.22 Cr.-4.25 Cr.8.42 Cr.
Capital Expenditures-361.55 Cr.-306.28 Cr.-180.54 Cr.-136.73 Cr.

Financials

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax1381.28 Cr.738.89 Cr.546.46 Cr.290.53 Cr.
Minority Interest14.53 Cr.13.63 Cr.15.54 Cr.15.54 Cr.
Net Income1314.59 Cr.742.11 Cr.531.45 Cr.279.07 Cr.
Selling General Administrative1030.89 Cr.936.17 Cr.810.29 Cr.757.79 Cr.
Gross Profit3524.24 Cr.2862.13 Cr.2415.21 Cr.2050.61 Cr.
Ebit1314.59 Cr.742.11 Cr.531.45 Cr.279.07 Cr.
Operating Income1314.59 Cr.742.11 Cr.531.45 Cr.279.07 Cr.
Other Operating Expenses971.98 Cr.975.33 Cr.890 Cr.834.42 Cr.
Interest Expense-8.61 Cr.-15.84 Cr.-18.30 Cr.-23.43 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense240.14 Cr.135.33 Cr.104.24 Cr.51.11 Cr.
Total Revenue5420.73 Cr.4649.86 Cr.3774.96 Cr.3285.17 Cr.
Total Operating Expenses4106.14 Cr.3907.75 Cr.3243.51 Cr.3006.10 Cr.
Cost of Revenue1896.49 Cr.1787.73 Cr.1359.75 Cr.1234.56 Cr.
Total Other Income Expense Net66.69 Cr.-3.22 Cr.15.01 Cr.11.46 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.1141.14 Cr.603.56 Cr.442.22 Cr.239.42 Cr.
Net Income Applicable to Common Shares1140.01 Cr.606.32 Cr.444.83 Cr.239.42 Cr.

Balance Sheet

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Intangible Assets114.20 Cr.136.32 Cr.176.95 Cr.83.36 Cr.
Capital Surplus96.52 Cr.48.87 Cr.48.87 Cr.43.99 Cr.
Total Liabilities1352.18 Cr.1618.72 Cr.1412.74 Cr.1428.73 Cr.
Stock Holder Equity4701.65 Cr.3627.48 Cr.3122.39 Cr.2688.57 Cr.
Minority Interest14.53 Cr.13.63 Cr.15.54 Cr.0
Other Liabilities196.43 Cr.288.38 Cr.227.11 Cr.161.37 Cr.
Total Assets6068.36 Cr.5259.83 Cr.4550.67 Cr.4117.30 Cr.
Common Stock25.37 Cr.25.27 Cr.25.27 Cr.25.24 Cr.
Retained Earnings4558.80 Cr.3519.43 Cr.3042.27 Cr.2610.70 Cr.
Other Liabilities174.26 Cr.176.31 Cr.174.39 Cr.187.15 Cr.
Good Will46.60 Cr.62.44 Cr.47.20 Cr.47.20 Cr.
Treasury Stock20.96 Cr.33.91 Cr.5.98 Cr.8.64 Cr.
Other Assets212.72 Cr.140.80 Cr.136.16 Cr.128.34 Cr.
Cash165.97 Cr.58.46 Cr.281.18 Cr.149.28 Cr.
Current Liabilities1133.13 Cr.1326.42 Cr.1097.50 Cr.1007.57 Cr.
Long Term Asset Charges1.95 Cr.2.01 Cr.1.84 Cr.1.74 Cr.
Short Long Term Debt66.60 Cr.67.91 Cr.114.41 Cr.154.51 Cr.
Other Stockholder Equity20.96 Cr.33.91 Cr.5.98 Cr.8.64 Cr.
Property Plant Equipment2146.45 Cr.1993.25 Cr.1782.56 Cr.1895.40 Cr.
Total Cur. Assets3436.96 Cr.2855.71 Cr.2377.75 Cr.1945.48 Cr.
Long Term Investments111.43 Cr.71.31 Cr.30.05 Cr.17.52 Cr.
Net Tangible Assets4540.85 Cr.3428.72 Cr.2898.24 Cr.2558.01 Cr.
Short Term Investments197.84 Cr.121.15 Cr.00
Net Receivables1014 Cr.1074.59 Cr.873.35 Cr.812.57 Cr.
Long Term Debt36.54 Cr.102.97 Cr.140.85 Cr.234.01 Cr.
Inventory1594.81 Cr.1323.12 Cr.1072.50 Cr.880.59 Cr.
Accounts Payable666.17 Cr.609.85 Cr.524.32 Cr.423.47 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account